Rajat Garg1, Manik Aggarwal1, Robert Butler2, Jean Paul Achkar3, Bret Lashner3, Jessica Philpott3, Benjamin Cohen3, Taha Qazi3, Florian Rieder3, Miguel Regueiro1,2,3, Benjamin Click4. 1. Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA. 2. Quantitative Health Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. 3. Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. 4. Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. clickb@ccf.org.
Abstract
INTRODUCTION: The efficacy and safety profile of ustekinumab (UST) in Crohn's disease (CD) is favorable; however, data in elderly patients are lacking. We aimed to assess the safety and efficacy of UST in elderly CD. METHODS: We performed a retrospective cohort study of CD patients classified as elderly (age ≥ 65 years at UST initiation) or nonelderly (<65 years) treated at a large, tertiary referral center. Outcomes assessed were clinical (measured by physician global assessment [PGA]) and steroid-free response, remission, adverse events, and postsurgical complications were compared by age category. Multivariable regression modeling and survival analysis was also performed. RESULTS: In total, 117 patients (elderly n = 39, nonelderly n = 78) were included in the study. Elderly patients had predominantly moderate disease (87.2%), while nonelderly had a higher proportion of severe disease activity (44.9%) (p = 0.001), though no differences in baseline endoscopic activity, prior biologic use, or steroid or immunomodulator use at baseline existed (p > 0.05 all). While nearly 90% patients in both groups experienced clinical response to UST, compared to nonelderly, elderly patients were less likely to achieve complete clinical remission (28.2% vs. 52.6%, p = 0.01). On regression modeling, age was not associated with clinical outcomes (p > 0.05 all). Mucosal healing was achieved in 26% elderly and 30% nonelderly patients (p = 0.74). There were no significant differences in infusion reactions (2.6% vs. 6.4%, p = 0.77), infection (5.2% vs. 7.7%, p = 0.7), or postsurgical complications (p = 0.99) by age category. CONCLUSION: UST is safe and effective in elderly CD. Although limited by sample size and retrospective design, such real-world data can inform biologic positioning in this IBD population.
INTRODUCTION: The efficacy and safety profile of ustekinumab (UST) in Crohn's disease (CD) is favorable; however, data in elderly patients are lacking. We aimed to assess the safety and efficacy of UST in elderly CD. METHODS: We performed a retrospective cohort study of CD patients classified as elderly (age ≥ 65 years at UST initiation) or nonelderly (<65 years) treated at a large, tertiary referral center. Outcomes assessed were clinical (measured by physician global assessment [PGA]) and steroid-free response, remission, adverse events, and postsurgical complications were compared by age category. Multivariable regression modeling and survival analysis was also performed. RESULTS: In total, 117 patients (elderly n = 39, nonelderly n = 78) were included in the study. Elderly patients had predominantly moderate disease (87.2%), while nonelderly had a higher proportion of severe disease activity (44.9%) (p = 0.001), though no differences in baseline endoscopic activity, prior biologic use, or steroid or immunomodulator use at baseline existed (p > 0.05 all). While nearly 90% patients in both groups experienced clinical response to UST, compared to nonelderly, elderly patients were less likely to achieve complete clinical remission (28.2% vs. 52.6%, p = 0.01). On regression modeling, age was not associated with clinical outcomes (p > 0.05 all). Mucosal healing was achieved in 26% elderly and 30% nonelderly patients (p = 0.74). There were no significant differences in infusion reactions (2.6% vs. 6.4%, p = 0.77), infection (5.2% vs. 7.7%, p = 0.7), or postsurgical complications (p = 0.99) by age category. CONCLUSION: UST is safe and effective in elderly CD. Although limited by sample size and retrospective design, such real-world data can inform biologic positioning in this IBD population.
Authors: Vineet S Rolston; Jessica Kimmel; Violeta Popov; Brian P Bosworth; David Hudesman; Lisa B Malter; Simon Hong; Shannon Chang Journal: Dig Dis Sci Date: 2020-05-22 Impact factor: 3.199
Authors: Manie Juneja; Leonard Baidoo; Marc B Schwartz; Arthur Barrie; Miguel Regueiro; Michael Dunn; David G Binion Journal: Dig Dis Sci Date: 2012-02-23 Impact factor: 3.199
Authors: Remo Panaccione; Silvio Danese; William J Sandborn; Christopher D O'Brien; Yiying Zhou; Hongyan Zhang; Omoniyi J Adedokun; Ilia Tikhonov; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Ellen J Scherl; Rupert W Leong; David S Rowbotham; Ramesh P Arasaradnam; Bruce E Sands; Colleen Marano Journal: Aliment Pharmacol Ther Date: 2020-10-21 Impact factor: 8.171
Authors: Gustavo Drügg Hahn; Jean-Frédéric LeBlanc; Petra Anna Golovics; Panu Wetwittayakhlang; Abdulrahman Qatomah; Anna Wang; Levon Boodaghians; Jeremy Liu Chen Kiow; Maryam Al Ali; Gary Wild; Waqqas Afif; Alain Bitton; Peter Laszlo Lakatos; Talat Bessissow Journal: World J Gastroenterol Date: 2022-09-07 Impact factor: 5.374